Deals Shaping The Medical Industry, April 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
You may also be interested in...
EU Indication Restricted For Novartis's Newly Approved Piqray
Piqray is now approved for use in 50 countries but not only did the novel breast cancer drug take longer to be approved in the EU than in the US, its indication is narrower in the EU.
Long-Awaited EU Review Questions 10-Year Orphan Exclusivity
The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."
‘Buy American’ Executive Order Receives Backlash
To build a “reliable long-term domestic production” of medicines and related supplies and to “minimize potential shortages,” US President Donald Trump has signed a ‘Buy American’ executive order. However, the move has left industry wondering if it is a sustainable solution.
Need a specific report? 1000+ reports available
Buy Reports